Compare Peloton Interactive Inc (PTON) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Peloton Interactive Inc vs TG Therapeutics Inc — how do they compare? Peloton Interactive Inc trades at $5.06 (market cap $2.21B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: TG Therapeutics Inc is far larger — about 3.9× Peloton Interactive Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals.
| PTON | TGTX | |
|---|---|---|
Market Cap | $2.21B | $8.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $9.00 | $59.06 |
52-Week Low | $3.71 | $26.94 |
Enterprise Value | $2.71B | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Peloton Interactive (PTON) trades at $5.04, down 6.67% amid bearish technical signals and mixed fundamentals. The company achieved its first full-year net profit in fiscal 2026 with a 2.58% net income margin, though revenue declined to $2.49B in 2025. Analyst sentiment is divided with a 50% buy rating but a consensus price target of $7.25, while technical indicators show strong bearish momentum with all moving averages signaling sell.
The outlook remains cautious as PTON balances profitability gains against subscriber declines and weak revenue growth. Investment opportunity exists if cost-cutting sustains margins, but risks include high debt load, competitive pressures, and insider selling activity. The stock trades near key support levels with institutional sentiment mixed.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
